Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model.

Gunn WG, Krause U, Lee N, Gregory CA.

Blood. 2011 Feb 3;117(5):1641-51. doi: 10.1182/blood-2010-09-308171. Epub 2010 Dec 1.

2.

Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy.

Krause U, Harris S, Green A, Ylostalo J, Zeitouni S, Lee N, Gregory CA.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4147-52. doi: 10.1073/pnas.0914360107. Epub 2010 Feb 11.

3.

GSK-3β inhibition promotes engraftment of ex vivo-expanded hematopoietic stem cells and modulates gene expression.

Ko KH, Holmes T, Palladinetti P, Song E, Nordon R, O'Brien TA, Dolnikov A.

Stem Cells. 2011 Jan;29(1):108-18. doi: 10.1002/stem.551.

4.

Small-molecule inhibitor of glycogen synthase kinase 3β 6-Bromoindirubin-3-oxime inhibits hematopoietic regeneration in stem cell recipient mice.

Shen S, Xu N, Klamer G, Ko KH, Khoo M, Ma D, Moore J, O'Brien TA, Dolnikov A.

Stem Cells Dev. 2015 Mar 15;24(6):724-36. doi: 10.1089/scd.2014.0230. Epub 2014 Dec 9.

PMID:
25329250
5.

Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss.

Wang FS, Ko JY, Weng LH, Yeh DW, Ke HJ, Wu SL.

Life Sci. 2009 Nov 4;85(19-20):685-92. doi: 10.1016/j.lfs.2009.09.009. Epub 2009 Sep 25.

PMID:
19782693
6.

Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.

Song EY, Palladinetti P, Klamer G, Ko KH, Lindeman R, O'Brien TA, Dolnikov A.

Exp Hematol. 2010 Oct;38(10):908-921.e1. doi: 10.1016/j.exphem.2010.06.001. Epub 2010 Jun 9.

PMID:
20540984
7.

GSK-3β inhibition promotes early engraftment of ex vivo-expanded haematopoietic stem cells.

Dolnikov A, Xu N, Shen S, Song E, Holmes T, Klamer G, O'Brien TA.

Cell Prolif. 2014 Apr;47(2):113-23. doi: 10.1111/cpr.12092. Epub 2014 Feb 12.

8.

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.

Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B, Mundy GR.

Blood. 2008 Mar 1;111(5):2833-42. Epub 2007 Dec 19.

9.

Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors.

Sinha D, Wang Z, Ruchalski KL, Levine JS, Krishnan S, Lieberthal W, Schwartz JH, Borkan SC.

Am J Physiol Renal Physiol. 2005 Apr;288(4):F703-13. Epub 2004 Nov 30.

PMID:
15572521
10.

GSK-3β inhibition preserves naive T cell phenotype in bone marrow reconstituted mice.

Shen S, Klamer G, Xu N, O'Brien TA, Dolnikov A.

Exp Hematol. 2013 Dec;41(12):1016-27.e1. doi: 10.1016/j.exphem.2013.08.006. Epub 2013 Sep 7.

PMID:
24018603
11.

Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.

Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q.

Leukemia. 2012 Sep;26(9):2114-23. doi: 10.1038/leu.2012.71. Epub 2012 Mar 19. Erratum in: Leukemia. 2015 Feb;29(2):515.

12.
13.

How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow.

Gregory CA, Gunn WG, Reyes E, Smolarz AJ, Munoz J, Spees JL, Prockop DJ.

Ann N Y Acad Sci. 2005 May;1049:97-106. Review.

PMID:
15965110
14.

Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth.

Holmes T, O'Brien TA, Knight R, Lindeman R, Shen S, Song E, Symonds G, Dolnikov A.

Stem Cells. 2008 May;26(5):1288-97. doi: 10.1634/stemcells.2007-0600. Epub 2008 Mar 6.

15.

Wnt-dependent osteogenic commitment of bone marrow stromal cells using a novel GSK3β inhibitor.

Cook DA, Fellgett SW, Pownall ME, O'Shea PJ, Genever PG.

Stem Cell Res. 2014 Mar;12(2):415-27. doi: 10.1016/j.scr.2013.10.002. Epub 2013 Oct 16.

16.

Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.

Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL.

J Bone Miner Res. 2006 Jun;21(6):910-20.

17.

Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A.

Martin L, Magnaudeix A, Esclaire F, Yardin C, Terro F.

Brain Res. 2009 Feb 3;1252:66-75. doi: 10.1016/j.brainres.2008.11.057. Epub 2008 Nov 30.

PMID:
19071093
18.

Enhanced Wnt/β-catenin signalling during tooth morphogenesis impedes cell differentiation and leads to alterations in the structure and mineralisation of the adult tooth.

Aurrekoetxea M, Lopez J, García P, Ibarretxe G, Unda F.

Biol Cell. 2012 Oct;104(10):603-17. doi: 10.1111/boc.201100075. Epub 2012 Aug 23.

PMID:
22671936
19.

Delayed treatment of 6-Bromoindirubin-3'-oxime stimulates neurogenesis and functional recovery after focal ischemic stroke in mice.

Wang LL, Li J, Gu X, Wei L, Yu SP.

Int J Dev Neurosci. 2017 Apr;57:77-84. doi: 10.1016/j.ijdevneu.2017.01.002. Epub 2017 Jan 19.

PMID:
28111255
20.

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.

Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI.

Cancer Res. 2007 May 15;67(10):4572-7. Epub 2007 May 10.

Supplemental Content

Support Center